MASTERINVEST Kapitalanlage GmbH Makes New Investment in Gilead Sciences, Inc. $GILD

MASTERINVEST Kapitalanlage GmbH acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 27,863 shares of the biopharmaceutical company’s stock, valued at approximately $3,089,000.

A number of other institutional investors have also recently made changes to their positions in GILD. Brighton Jones LLC grew its holdings in Gilead Sciences by 20.6% during the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $215,000. Kovitz Investment Group Partners LLC boosted its position in shares of Gilead Sciences by 160.9% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 94,827 shares of the biopharmaceutical company’s stock valued at $10,625,000 after acquiring an additional 58,485 shares during the last quarter. Trivium Point Advisory LLC purchased a new position in shares of Gilead Sciences in the first quarter valued at $206,000. Finally, Fox Run Management L.L.C. increased its position in Gilead Sciences by 5.6% in the first quarter. Fox Run Management L.L.C. now owns 5,995 shares of the biopharmaceutical company’s stock worth $672,000 after purchasing an additional 319 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on GILD shares. TD Cowen increased their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Morgan Stanley increased their price target on shares of Gilead Sciences from $147.00 to $151.00 and gave the company an “overweight” rating in a report on Friday. Daiwa Capital Markets boosted their price objective on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. UBS Group raised Gilead Sciences to a “hold” rating in a research note on Thursday, December 4th. Finally, The Goldman Sachs Group lifted their target price on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $131.13.

Insider Activity

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.10, for a total value of $356,515.50. Following the completion of the sale, the director directly owned 1,339 shares of the company’s stock, valued at $170,186.90. The trade was a 67.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares in the company, valued at approximately $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 135,757 shares of company stock valued at $16,616,127. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Down 2.3%

Shares of NASDAQ GILD opened at $120.40 on Friday. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The firm has a 50-day simple moving average of $121.89 and a two-hundred day simple moving average of $115.76. The company has a market cap of $149.38 billion, a P/E ratio of 18.67, a PEG ratio of 0.67 and a beta of 0.32. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the prior year, the business posted $2.02 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. The ex-dividend date is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.